SIGA Technologies announced deliveries of oral TPOXX to HHS valued at approximately $32 million
On Jun. 25, 2020, SIGA Technologies announced the deliveries of oral TPOXX (tecovirimat) to the U.S. Department of…
-
-
Biotechnology | Diagnostics | Disease | Neurology | NIH | Therapeutics
Seattle researchers teamed up to build hi-res brain map of Alzheimer’s disease
On Jun. 25, 2020, the Allen Institute announced a new a new $40.5 million collaborative research center in…
-
University of Alberta researcher to test whether COVID-19 antibodies provide long-term immunity
On Jun. 25, 2020, the University of Alberta (U of A) announced a study that will analyze thousands…
-
The FDA approved new therapy for Dravet Syndrome
On Jun. 25, 2020, the U.S. Food and Drug Administration (FDA) approved Fintepla (fenfluramine), a Schedule IV controlled…
-
RedHill Biopharma announced data from severe COVID-19 patients showed substantial benefit to patients
On Jun. 24, 2020, RedHill Biopharma announced that results from the treatment of the first severe COVID-19 patients…
-
Why men may fare worse than women against SARS-CoV-2
On Jun. 24, 2020, Howard Hughes Medical Institute (HHMI) investigators reported that data from COVID-19 cases around the…
-
New Oxford University co-led platform accelerated COVID-19 tests into real-world use
On Jun. 24, 2020, the University of Oxford that the COVID-19 National DiagnOstic Research and Evaluation Platform (CONDOR)…
-
Mateon selected by IBM Watson Health for use of IBM Clinical Development Solution to support clinical COVID-19 vaccine candidates
On Jun. 24, 2020, Oncotelic, a wholly owned subsidiary of Mateon Therapeutics, announced that IBM has granted access…
-
FibroGen announced first patient enrolled in Pamrevlumab clinical trial in patients hospitalized in US with acute COVID-19
On Jun. 23, 2020, FibroGen announced it has started enrollment for a Phase II clinical trial of pamrevlumab…
-
Mateon selected IQVIA for its randomized, controlled, multi-menter clinical study to test OT-101 as treatment for COVID-19 patients
On Jun. 23, 2020, Mateon Therapeutics, a leading developer of TGF-β therapeutics, announced it has selected IQVIA to…
-
Catalent partnered with ViralClear Pharmaceuticals on potential treatment for COVID-19
On Jun. 22, 2020, Catalent announced that it is partnering with ViralClear Pharmaceuticals, a subsidiary of BioSig Technologies,…
-
Taconic Biosciences announced distribution of critical COVID-19 mouse model
On Jun. 22, 2020, Taconic Biosciences announced an exclusive agreement with the University of Texas Medical Branch at…
-
The NIH halted clinical trial of hydroxychloroquine
On Jun. 20, 2020, the National Institutes of Health (NIH) announced that a clinical trial to evaluate the…
-
COVID-19 pandemic dramatically increased out-of-hospital cardiac arrest cases and deaths in New York City
On Jun. 19, 2020, The COVID-19 pandemic in New York City caused a surge in out-of-hospital cardiac arrests…
-
Biotechnology | FDA | Oncology | Rare Disease | Therapeutics
Ultragenyx and Kyowa Kirin Announce U.S. FDA Approval of Crysvita® (burosumab) for Treatment of Tumor-Induced Osteomalacia
On Jun. 18, 2020, Ultragenyx Pharmaceutical and Kyowa Kirin announced that the U.S. Food and Drug Administration (FDA)…
-
Tonix Pharma and Southern Research announced expansion of COVID-19 vaccine collaboration
On Jun. 18, 2020, Tonix Pharmaceuticals announced an expansion of its strategic collaboration with Southern Research to include…
-
Innovation Pharma’s Brilacidin inhibited SARS-CoV-2 by 97 percent in a human lung cell line
On Jun. 17, 2020, Innovation Pharma reported receiving data from ongoing laboratory testing being conducted at a U.S….
-
Aclaris Therapeutics supported investigator-initiated clinical trial of ATI-450 for cytokine release syndrome in hospitalized COVID-19 patients
On Jun. 17, 2020, Aclaris Therapeutics announced that the FDA had allowed an investigational new drug application to…
-
Oxford University and Bvlgari announced collaboration to fight COVID-19 and future pandemics
On Jun. 17, 2020, Bvlgari, the Italian luxury brand, announced plans to support research into COVID-19 and vaccine…
-
ViralClear opened enrollment with first patient dosing in phase II human trial of anti-viral MMPD oral solution for treatment of COVID-19
On Jun. 17, 2020, BioSig Technologies, and its subsidiary, ViralClear, announced that it had commenced patient enrollment with…
-
WHO announced preliminary results about dexamethasone use in treating critically ill COVID-19 patients
On Jun. 16, 2020, the World Health Organization (WHO) announced that initial clinical trial results from the United…
-
COVID-19 | Infectious Disease | NIH | Therapeutics | Vaccine
All of Us Research Program launched COVID-19 research initiatives
On Jun. 16, 2020, the All of Us Research Program, part of the National Institutes of Health, announced…
-
Low-cost dexamethasone reduced death by up to one third in hospitalised patients with severe respiratory complications of COVID-19
On Jun. 16, 2020, the University of Oxford reported that overall dexamethasone reduced the 28-day mortality rate by…
-
Pneumonia vaccine price dropped dramatically for lower-income countries thanks to the Gavi pneumococcal Advance Market Commitment
On Jun. 16, 2020, lower-income countries across the world have access life-saving pneumococcal conjugate vaccines, which protect against…
-
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Non-Profit Research | Therapeutics | Vaccine
San Diego’s scientific and medical institutes collaborated on large-scale research program to study spread of COVID-19
On Jun. 16, 2020, a consortium that includes many of San Diego’s top medical and scientific research institutes…
-
The FDA warned of newly discovered potential drug interaction that may reduce effectiveness of COVID-19 treatment
On Jun. 15, 2020, the U.S. Food and Drug Administration (FDA) warned health care providers about a newly…
-
The FDA revoked Emergency Use Authorization for chloroquine and hydroxychloroquine
On Jun. 15, 2020, the U.S. Food and Drug Administration (FDA) revoked the emergency use authorization (EUA) that…
-
Biotechnology | Diagnostics | Disease | FDA | Medical Device | Neurology | Therapeutics
The FDA permitted marketing of first game-based digital therapeutic to improve attention function in children with ADHD
On Jun. 15, 2020, the U.S. Food and Drug Administration (FDA) permitted marketing of the first game-based digital…
-
Lilly begans phase 3 clinical trial with baricitinib for hospitalized COVID-19 patients
On Jun. 15, 2020, Eli Lilly announced that the first patient has been enrolled in a Phase 3…
-
SIGA Technologies announced Department of Defense increased funding to develop Post Exposure prophylactic indication for TPOXX
On Jun. 15, 2020, SIGA Technologies announced that it had been awarded a multi-year contract from the United…
